Rexahn Pharma up 10%

Nano cap biotech Rexahn Pharmaceuticals (RNN) enjoys a pop in today's trading. Shares have eased a bit from the intraday high of $1.47, but are still up ~9% at $1.36.

The firm disclosed initial results from its Phase 1 clinical trial of Supinoxin (RX-5902). Three patients have received two - six cycles of treatment. All doses were well tolerated.

Some observers perceive the action as proof of investors' overexuberance with all things biotech.

Comments (2)
    , contributor
    Comments (78) | Send Message
    4000 shares and holding. I expect to make some money this year with RNN.
    11 Mar 2014, 02:22 PM Reply Like
  • StuckeyStocks
    , contributor
    Comments (12) | Send Message
    If only I was up early enough this morning to sell, and lock in the gains... SMH at least there will be many other chances in the near future.
    11 Mar 2014, 04:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs